191871-32-6

Basic information

• Product Name: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE
• Synonyms: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE;Benzeneacetic acid, 4-[[[(1,1-diMethylethoxy)carbonyl]aMino]Methyl]-, Methyl ester
• CAS NO: 191871-32-6
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33
• Mol File: 191871-32-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(191871-32-6)
• EPA Substance Registry System: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(191871-32-6)

Safety Data

• Hazardous Substances Data: 191871-32-6(Hazardous Substances Data)

Upstream product

• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 17833-56-6 ester monomethylique de l'acide p-phenylene diacetique 
• 4129-17-3 diphenylphosphoranyl azide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 444807-46-9 2-(4-(aminomethyl)phenyl)acetic acid methyl ester 
• 52798-01-3 methyl 4-cyanobenzeneacetate 

Downstream Products

• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 
• 808753-20-0 2-(4-aminomethyl-phenyl)-N-methyl-N-(1-phenyl-2-pyrrolidin-1-yl-ethyl)-acetamide 
• 808753-17-5 [4-({methyl-[1-(S)-phenyl-2-pyrrolidin-1-yl-ethyl]-carbamoyl}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 99075-25-9 (4-aminomethylphenyl)-acetic acid methyl ester hydrochloride 

Relevant articles and documents

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

Some κ opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 μM) while displaying high affinity toward the cloned human κ opioid receptor, good κ/δ and κ/μ selectivity, and potent in vitro and in vivo agonist activity.

Sulfonylamino phenylacetamide derivatives and methods of their use

Sulfonylamino phenylacetamide derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to κ opioid receptors; (2) display good opioid receptor selectivity of κ versus μ and κ versus δ; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

Benzoxazepinones and their use as squalene synthase inhibitors

There is disclosed a compound represented by the formula [I]: wherein R1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X1-X2-Ar-X3-X4-COOH (wherein X1 and X4 are a bond or alkylene group, X2 and X3 are a bond, -O-, -S-, Ar is divalent aromatic group etc.), R2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.